Protalix Biotherapeutics Inc Stock TEL AVIV STOCK EXCHANGE
Equities
US74365A1016
Biotechnology & Medical Research
Sales 2024 * | 74.06M 28.2B | Sales 2025 * | 127M 48.49B | Capitalization | 86.2M 32.82B |
---|---|---|---|---|---|
Net income 2024 * | 17M 6.47B | Net income 2025 * | 70M 26.65B | EV / Sales 2024 * | 1.16 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.68 x |
P/E ratio 2024 * |
5.62
x | P/E ratio 2025 * |
1.46
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.23% |
Latest transcript on Protalix Biotherapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 19-06-29 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 19-07-21 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 20-07-04 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 19-11-30 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 19-11-30 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 14-10-31 |
1st Jan change | Capi. | |
---|---|---|
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.64% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |